These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 9229743

  • 21. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi M.
    Cancer; 2006 Dec 15; 107(12):2842-9. PubMed ID: 17103443
    [Abstract] [Full Text] [Related]

  • 22. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S, Suzuki M, Yamamoto N, Iida T, Kimura H.
    Anticancer Res; 2004 Dec 15; 24(3b):1941-6. PubMed ID: 15274381
    [Abstract] [Full Text] [Related]

  • 23. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T.
    Anticancer Res; 2001 Dec 15; 21(4B):3085-92. PubMed ID: 11712815
    [Abstract] [Full Text] [Related]

  • 24. [The significance of tumor-associated antigens in the diagnosis and therapeutic control of bronchial cancer].
    Gropp C, Luster W, Havemann K.
    Prax Klin Pneumol; 1982 Dec 15; 36(12):491-9. PubMed ID: 7163127
    [No Abstract] [Full Text] [Related]

  • 25. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P.
    Clin Cancer Res; 2008 Dec 01; 14(23):7813-21. PubMed ID: 19047109
    [Abstract] [Full Text] [Related]

  • 26. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.
    Muley T, Fetz TH, Dienemann H, Hoffmann H, Herth FJ, Meister M, Ebert W.
    Lung Cancer; 2008 Jun 01; 60(3):408-15. PubMed ID: 18083270
    [Abstract] [Full Text] [Related]

  • 27. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N.
    Anticancer Res; 2003 Jun 01; 23(2A):885-93. PubMed ID: 12820318
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W, Hoppe M, Muley T, Drings P.
    Anticancer Res; 1997 Jun 01; 17(4B):2875-8. PubMed ID: 9329552
    [Abstract] [Full Text] [Related]

  • 33. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Jun 01; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Tumor markers for lung neoplasm].
    Sekido Y.
    Nihon Rinsho; 2002 May 01; 60 Suppl 5():229-32. PubMed ID: 12101663
    [No Abstract] [Full Text] [Related]

  • 36. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S, Schleucher N, Weber R, Neumann R, Seeber S.
    Oncol Rep; 2003 May 01; 10(2):475-82. PubMed ID: 12579292
    [Abstract] [Full Text] [Related]

  • 37. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
    Muley T, Dienemann H, Ebert W.
    Anticancer Res; 2004 May 01; 24(3b):1953-6. PubMed ID: 15274383
    [Abstract] [Full Text] [Related]

  • 38. [Lung cancer].
    Komagata H, Yoneda S.
    Gan To Kagaku Ryoho; 2004 Oct 01; 31(10):1609-13. PubMed ID: 15508459
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Tumor markers as prognostic factors in treated non-small cell lung cancer.
    Trapé J, Buxo J, Pérez de Olaguer J, Vidal C.
    Anticancer Res; 2003 Oct 01; 23(5b):4277-81. PubMed ID: 14666638
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.